West London Mental Health NHS Trust

West London Mental Health NHS Trust Performance in Initiating Q4 16/17

HRA Approval Studies

Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Comments
16/NE/0191	202345	HRA Approval	A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB)	Yes	01/11/2016	Yes	09/05/2016	24/08/2016	22/08/2016	24/08/2016	30/08/2016	Please Select...	02/09/2016	

West London Mental Health NHS Trust Performance in Delivery Q4 16/17

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
150835/LNW	150835	DEME 3598 – STARBRIGHT Randomised, double blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild moderate Alzheimer's disease treated with an acetylcholinesterase inhibitor; study 3	Number Agreed	8	8	Date Agreed	30/06/2016	9	30/06/2016	9	Recruitment Finished	Recruitment target achieved
12/NW/0723	115205	A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY EXTENSION OF PHASE II STUDIES ABE4869g AND ABE4955g IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE	Number Agreed	1	1	Date Agreed	31/05/2016	1	31/05/2016	1	Recruitment Finished	Recruitment target achieved
13/LO/1768	136392	A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)	Number Agreed	10	10	Date Agreed	24/11/2016	4	24/11/2016	4	Recruitment Finished	Recruitment target not achieved